Bright Minds Biosciences (DRUG) - 2024 Q3 - Quarterly Report

Bright Minds Biosciences Inc. Condensed Interim Consolidated Financial Statements For the nine months ended June 30, 2024 and 2023 (Expressed in Canadian Dollars) 1 | P a g e June 30, September 30, | --- | --- | --- | --- | |---------------------------------|-------|------------------|----------------| | As at | Notes | 2024 (unaudited) | 2023 (audited) | | | | $ | $ | | ASSETS | | | | | Current Assets | | | | | Cash and cash equivalents | 8 | 6,190,244 | 6,747,986 | | Sales tax receivable | | 17,236 | 36,9 ...